WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN) today announced that encouraging clinical findings with the targeted anticancer compounds IMGN242 and AVE1642 were reported at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL.
